These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37391059)

  • 1. Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders.
    Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
    Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3387-3396.e1. PubMed ID: 37391059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease.
    Narula N; Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W
    Am J Gastroenterol; 2024 Jul; 119(7):1355-1364. PubMed ID: 38235763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial.
    Danese S; Sands BE; Abreu MT; O'Brien CD; Bravatà I; Nazar M; Miao Y; Wang Y; Rowbotham D; Leong RWL; Arasaradnam RP; Afif W; Marano C
    Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2858-2867.e5. PubMed ID: 35276329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study.
    Narula N; Wong ECL; Marshall JK; Jairath V; Dulai PS; Reinisch W
    Am J Gastroenterol; 2023 Jan; 118(1):121-128. PubMed ID: 36066459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sands BE; Sandborn WJ; Panaccione R; O'Brien CD; Zhang H; Johanns J; Adedokun OJ; Li K; Peyrin-Biroulet L; Van Assche G; Danese S; Targan S; Abreu MT; Hisamatsu T; Szapary P; Marano C;
    N Engl J Med; 2019 Sep; 381(13):1201-1214. PubMed ID: 31553833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Placebo Induction Response and Remission in Ulcerative Colitis.
    Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1050-1060.e9. PubMed ID: 36029969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
    Dhaliwal J; McKay HE; Deslandres C; Debruyn J; Wine E; Wu A; Huynh H; Carman N; Crowley E; Church PC; Walters TD; Ricciuto A; Griffiths AM;
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1300-1308. PubMed ID: 33909911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis.
    Li K; Marano C; Zhang H; Yang F; Sandborn WJ; Sands BE; Feagan BG; Rubin DT; Peyrin-Biroulet L; Friedman JR; De Hertogh G
    Gastroenterology; 2020 Dec; 159(6):2052-2064. PubMed ID: 32853634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality register.
    Thunberg J; Björkqvist O; Hedin CRH; Forss A; Söderman C; Bergemalm D; ; Olén O; Hjortswang H; Strid H; Ludvigsson JF; Eriksson C; Halfvarson J
    United European Gastroenterol J; 2022 Sep; 10(7):631-639. PubMed ID: 35834389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
    Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F
    United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting Endoscopic Improvement in Ulcerative Colitis Using the Ulcerative Colitis Severity Index.
    Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
    Inflamm Bowel Dis; 2024 Mar; 30(3):370-381. PubMed ID: 37116893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
    Adedokun OJ; Xu Z; Marano C; O'Brien C; Szapary P; Zhang H; Johanns J; Leong RW; Hisamatsu T; Van Assche G; Danese S; Abreu MT; Sands BE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2244-2255.e9. PubMed ID: 31816446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study.
    Amiot A; Filippi J; Abitbol V; Cadiot G; Laharie D; Serrero M; Altwegg R; Bouhnik Y; Peyrin-Biroulet L; Gilletta C; Roblin X; Pineton de Chambrun G; Vuitton L; Bourrier A; Nancey S; Gornet JM; Nahon S; Bouguen G; Viennot S; Pariente B; Fumery M;
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1039-1046. PubMed ID: 32291786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data.
    Philip G; Cornillie F; Adedokun JO; Melsheimer R; Rutgeerts P; Colombel JF; Marano C
    J Crohns Colitis; 2019 Sep; 13(10):1257-1264. PubMed ID: 30847474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis.
    Wong ECL; Hasan B; Dulai PS; Marshall JK; Reinisch W; Narula N
    Scand J Gastroenterol; 2023 Jan; 58(1):7-14. PubMed ID: 35909369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study.
    Yarur AJ; Bruss A; Moosreiner A; Beniwal-Patel P; Nunez L; Berens B; Colombel JF; Targan SR; Fox C; Melmed GY; Abreu MT; Deepak P
    Gastroenterology; 2023 Oct; 165(4):963-975.e5. PubMed ID: 37499955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Hibi T; D'Haens GR; Tuttle JL; Krueger K; Friedrich S; Durante M; Arora V; Naegeli AN; Schmitz J; Feagan BG
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):105-115.e14. PubMed ID: 32950748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-reactive protein-to-lymphocyte ratio is a novel biomarker for predicting the long-term efficacy of ustekinumab treatment in ulcerative colitis.
    Koshiba R; Kakimoto K; Mizuta N; Numa K; Kinoshita N; Nakazawa K; Hirata Y; Miyazaki T; Higuchi K; Nakamura S; Nishikawa H
    PLoS One; 2024; 19(8):e0305324. PubMed ID: 39208267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.